Fluocinolone insert's impact on overall risk of procedures: In an analysis of FAME study data, risk of subsequent procedures was reduced in treated patients

Retina Today

Volumn , Issue OCTOBER, 2010, Pages 72-74

  Pearson, P Andrew ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82255166851     PISSN: None     EISSN: 18250572     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Centers for Disease Control and Prevention. Diabetes is common, disabling, deadly, and on the rise. http://www.cdc.gov/Features/dsDiabetesTrends/. Accessed September 21, 2010.
2. Alimera announces positive results from the two phase 3 FAME trials of Iluvien in patients with diabetic macular edema. http://investor.alimerasciences.com/releases.cfm. Accessed September 21, 2010.
3. Pearson PA. Fluocinolone acetonide insert (Iluvien) phase 3 studies: reduced overall risk of procedures to treat diabetic retinopathy and elevation of IOP. Paper presented at: American Society of Retina Specialists annual meeting; Vancouver, Canada.